Abstract
Patients with cancer are frequently exposed to risk of renal injuries associated with disease-related or iatrogenic causes. Nephrotoxicity is a potential adverse effect of anti-cancer agents and may result in a variety of functional abnormalities, including glomerular or tubular dysfunction, hypertension and disturbance of the renal endocrine function. In this review article, we comprehensively discuss the incidence, clinical presentation, prevention and management of anti-cancer agent-induced renal dysfunction. We focus on both relatively new anti-cancer agents (bevacizumab, gefitinib, gemcitabine, imatinib, rituximab and trastuzumab) and traditional agents (cisplatin, methotrexate, ifosfamide and taxanes) to cover a selection of the most frequently used anti-cancer agents. Increased understanding of the mechanism of renal injury by these agents is considered to be important for developing novel anti-cancer agents that have far fewer adverse effects on kidneys.
Keywords: Acute kidney injury, anti-cancer agents, cisplatin, chemotherapy, electrolyte abnormality, nephrotoxicity.
Anti-Cancer Agents in Medicinal Chemistry
Title:Anti-Cancer Agent-Induced Nephrotoxicity
Volume: 14 Issue: 7
Author(s): Hirotaka Fukasawa, Ryuichi Furuya, Hideo Yasuda, Tatsuo Yamamoto, Akira Hishida and Masatoshi Kitagawa
Affiliation:
Keywords: Acute kidney injury, anti-cancer agents, cisplatin, chemotherapy, electrolyte abnormality, nephrotoxicity.
Abstract: Patients with cancer are frequently exposed to risk of renal injuries associated with disease-related or iatrogenic causes. Nephrotoxicity is a potential adverse effect of anti-cancer agents and may result in a variety of functional abnormalities, including glomerular or tubular dysfunction, hypertension and disturbance of the renal endocrine function. In this review article, we comprehensively discuss the incidence, clinical presentation, prevention and management of anti-cancer agent-induced renal dysfunction. We focus on both relatively new anti-cancer agents (bevacizumab, gefitinib, gemcitabine, imatinib, rituximab and trastuzumab) and traditional agents (cisplatin, methotrexate, ifosfamide and taxanes) to cover a selection of the most frequently used anti-cancer agents. Increased understanding of the mechanism of renal injury by these agents is considered to be important for developing novel anti-cancer agents that have far fewer adverse effects on kidneys.
Export Options
About this article
Cite this article as:
Fukasawa Hirotaka, Furuya Ryuichi, Yasuda Hideo, Yamamoto Tatsuo, Hishida Akira and Kitagawa Masatoshi, Anti-Cancer Agent-Induced Nephrotoxicity, Anti-Cancer Agents in Medicinal Chemistry 2014; 14 (7) . https://dx.doi.org/10.2174/1871520614666140127105809
DOI https://dx.doi.org/10.2174/1871520614666140127105809 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inhibition of RET Activated Pathways: Novel Strategies for Therapeutic Intervention in Human Cancers
Current Pharmaceutical Design Editorial [Hot Topic: Inflammation in Atherosclerosis: Current Therapeutic Approaches (Executive Guest Editor: Dimitris Tousoulis)]
Current Pharmaceutical Design Difference in Blood Pressure Measurements Between Arms: Methodological and Clinical Implications
Current Pharmaceutical Design Massively Parallel Screening of the Receptorome
Combinatorial Chemistry & High Throughput Screening Independent Relationship between Serum Osteocalcin and Uric Acid in a Cohort of Apparently Healthy Obese Subjects
Endocrine, Metabolic & Immune Disorders - Drug Targets Use of Chronic Disease Registries to Optimize Cardiovascular Health
Current Vascular Pharmacology Vitexin with its Derivatives is Responsible for the Cholinomimetic Properties of <i>Penianthus longifolius</i> Extract which Stimulates Muscarinic Receptors
The Natural Products Journal Contemporary Review of Drugs Used to Treat Obesity
Cardiovascular & Hematological Agents in Medicinal Chemistry Bariatric Surgery - Effects on Obesity and Related co-Morbidities
Current Diabetes Reviews Water Soluble Vitamins and their Role in Diabetes and its Complications
Current Diabetes Reviews Editorial: Management of Elevated Heart Rate in Essential Hypertension: Pathophysiological Insights and Therapeutic Approach
Current Pharmaceutical Design Visual Spatial Attention Training Improve Spatial Attention and Motor Control for Unilateral Neglect Patients
CNS & Neurological Disorders - Drug Targets Effects of Vitamin E and C on Placental Oxidative Stress: An In Vitro Evidence for the Potential Therapeutic or Prophylactic Treatment of Preeclampsia
Medicinal Chemistry L-4F Differentially Alters Plasma Levels of Oxidized Fatty Acids Resulting in more Anti-Inflammatory HDL in Mice
Drug Metabolism Letters High Blood Pressure and the Risk of Stroke
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Therapeutic Implications of Renin-Angiotensin System Blockade in Diabetic Retinopathy
Current Pharmaceutical Biotechnology Human Fibrinogen Adsorption on Latex Particles at pH 7.4 Studied by Electrophoretic Mobility and AFM Measurements
Current Topics in Medicinal Chemistry Targeting Antioxidants to Mitochondria: A Potential New Therapeutic Strategy for Cardiovascular Diseases
Current Pharmaceutical Design Editorial [Hot Topic: Progressive and Unconventional Pharmacotherapeutic Approaches to Alzheimers Disease Therapy (Guest Editors: Stuart Maudsley & Wayne Chadwick)]
Current Alzheimer Research Possible Involvement of TRP Channels in Cardiac Hypertrophy and Arrhythmia
Current Topics in Medicinal Chemistry